“Acute Repetitive Seizures Market Report is set to have rapid growth due high prevalence of disease and Innovative research and development at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report

04 September 2019
Pharma

Visiongain has launched a new pharma report Acute Repetitive Seizures Market Forecast : By Product (USL-261, NRL-1, AZ-002, Diastat Rectal Gel), By Region and Segment Forecasts.

The global Acute Repetitive Seizures market is poised for rapid growth between 2019 and 2029. High unmet medical clinical for patients, as well as caregivers and the availability of an advanced product pipeline are some of the main factors that should favor market growth. Drug therapy is effective for most patients with cluster convulsions. However, there are a significant number of therapeutic challenges and unmet medical needs including drug-induced seizures, adverse reactions and a lack of anti-epileptic agents that can prevent the development of convulsions and its comorbidities.

The market is currently driven by generic drugs that mainly include oral benzodiazepines (diazepam and lorazepam). Rectal diazepam is the only drug approved for use in the United States and buccal midazolam in the European Union. Other drugs, such as diazepam (oral and intramuscular), midazolam (oral, intranasal, intramuscular), lorazepam (oral, intranasal, sublingual) and progesterone are mainly used off label. The market should be consolidated with a few large companies and high market shares.

Leading companies featured in the report include UCB S.A. Belgium, Neurelis, Valeant Pharmaceuticals North America LLC., Alexza Pharmaceuticals, VERITON PHARMA and others

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Cancer Diagnostics Market Report 2021-2031

Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.

19 April 2021

Read

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

Read

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

Read

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever